Triple-negative cancer represents approximately 15% of breast cancers. It is very aggressive with a treatment resistance rate of 40% to 50% of cases.
Two teams from the Lyon Cancer Research Center (CRCL) working on this cancer are currently financially supported by the Arc foundation.
The Inspire project
As part of the SIGNI’IT 23 call for projects, the foundation will support the Inspire project, led by Christophe Caux, immunologist, and the Dr Olivier Tredan. This project aims to identify biomarkers making it possible to predict the effectiveness of two immunotherapies combined with radiotherapy in women with triple-negative breast cancer who do not respond to neo-adjuvant chemotherapy, administered before surgery.
The Meteor Project
An “Arc Foundation Project” grant of €50,000 is also paid, from January 2023 to December 2024, to the Meteor du D project.r Olivier Tredan and Muriel Le Romancer, Inserm research director, who aims to better understand resistance to treatments by deciphering molecular mechanisms that are involved in DNA repair, such as the BRCA1 and BRCA2 proteins, for example. .